Latebreakers: New indication granted for oncology product

September 17, 2007

Dexrazoxane approved for a new indication.

Dexrazoxane for injection, from TopoTarget A/S, is now approved for treatment of extravasation resulting from intravenous anthracycline chemotherapy. The new kit, called Totect, is already marketed in Europe and contains 10 vials, 500 mg each, of dexrazoxane and three bags of diluent. Dexrazoxane was previously approved to protect against cardiomyopathy in certain women receiving doxorubicin treatment for metastatic breast cancer. The drug works as a strong chelating agent and prevents the formation of iron-anthracycline complexes that cause oxidative damage to tissues and also inhibits the action of topoisomerase II. According to TopoTarget, the new kit will be available here by the end of 2007.